European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Forschungsinstitut für molekulare Pathologie GmbH, Vienna, Austria

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

Forschungsinstitut für molekulare Pathologie GmbH

Identification

Fb
Firmenbuch 082531w
Lei
529900XIA762B58MYP48
EUID
ATBRA.082531-000

Address

Campus-Vienna-Biocenter 1 Viehmarktgasse 2B, 1030 Wien, Austria

Financials

History

Marketing & Tech

Network

Loading network

Publications

10 Oct 2025
Annual report for the year ending 31/12/2024 · Balance sheet for 31/12/2024
2 May 2025 via C.H. Boehringer Sohn AG & Co. KG also 02/10/2024, 21/12/2022, 22/12/2021, 15/12/2020, 08/01/2020, 08/01/2020, 03/01/2018, 12/01/2017, 25/02/2016, 17/04/2015, 14/05/2014, 14/02/2013, 16/12/2011, 21/12/2010, 22/12/2009, 11/12/2008, 19/02/2008
Shareholder: C.H. Boehringer Sohn AG & Co. KG
5 Feb 2025 via Boehringer Ingelheim International GmbH also 16/02/2024, 13/03/2023, 13/03/2023, 12/01/2022, 12/01/2022, 13/02/2020, 13/02/2020, 23/01/2019, 23/01/2019, 01/02/2018, 01/02/2018, 09/01/2017, 09/01/2017, 02/12/2015, 02/12/2015, 05/12/2012, 10/01/2011, 10/01/2011
Shareholder: Boehringer Ingelheim International GmbH
6 Sept 2024
Annual report for the year ending 31/12/2023
12 Sept 2023
Annual report for the year ending 31/12/2022
1 Jun 2023 in Sat
State Aid (€1,770,731): FFG Industry Guideline, 2022
14 Feb 2023
Authorized signatory (ppa): Tanja Winkler · No longer Authorized signatory (ppa) (1)
13 Sept 2022
Annual report for the year ending 31/12/2021
23 Nov 2021
Annual report for the year ending 31/12/2020
28 Oct 2020
Annual report for the year ending 31/12/2019
10 Feb 2020 in Sat
State Aid (€3,000,000): promotion of applied research, development and innovation on the basis of the Austrian Research Promotion Agency (mbH)
5 Sept 2019
Annual report for the year ending 31/12/2018
15 Nov 2018
Annual report for the year ending 31/12/2017
20 Dec 2017
No longer Shareholder (1) · Shareholder: Boehringer Ingelheim International GmbH · Capital: €36,336
Year 2014 in Fts
5 EU fundings (total €4,677,332): The Cellular and Molecular Basis of Magnetoreception …
17 Mar 2014 via Boehringer Ingelheim Verwaltungs GmbH also 07/12/2012
Shareholder: Boehringer Ingelheim Verwaltungs GmbH
Year 2013 in Fts
4 EU fundings (total €1,873,315): Systemic Analysis of Chromatin-Regulatory Genes in Pdac Using Advanced in Vivo Rnai …
6 Mar 2013
Managing Director: Jan-Michael Peters · No longer Authorized signatory (ppa): Jan-Michael Peters · No longer Managing Director (1)
Year 2012 in Fts
4 EU fundings (total €5,669,064): Transcriptional Networks Controlling Lymphocyte Development …
1 Feb 2011 in Fts
EU funding (€349,045): 262067 - Prime-XS - FP7 Infra2010
Year 2010 in Fts
6 EU fundings (total €4,225,990): Mitosys …
Year 2009 in Fts
4 EU fundings (total €2,765,211): Meiosys …
1 Oct 2008 in Fts
EU funding (€714,850): KinetoCore
1 Oct 2008 in Fts
EU funding (€185,136): KinetoCore
1 Jul 2008
No longer Authorized signatory (ppa) (1)
7 Mar 2008
Authorized signatory (ppa): Jan-Michael Peters
1 Mar 2008 in Fts
EU funding (€155,259): PAX5Targets
10 Feb 2006
Managing Director (1) · No longer Managing Director (1)
9 Feb 2005
Managing Director: Harald Isemann · No longer Authorized signatory (ppa) (2) · No longer Managing Director (1)
10 Sept 2004
No longer Authorized signatory (ppa) (1)
14 Apr 2004
Authorized signatory (ppa): Harald Isemann
28 Dec 2002
Managing Director (1) · No longer Managing Director (1)
26 Apr 2002
Shareholder (1) · Shareholder: Boehringer Ingelheim International GmbH · Capital: €36,336
18 Dec 2001
Shareholder (1) · No longer Shareholder (1) · Capital: 500,000 ATS
2 Sept 1998
Managing Director (1) · No longer Managing Director (1)
13 Aug 1997
Authorized signatory (ppa) (1)
15 Jan 1997
Managing Director (2) · No longer Managing Director (1)
12 May 1994
Shareholder (1) · Shareholder: Boehringer Ingelheim International GmbH · No longer Shareholder: Genentech Inc., San Franciso, USA · Capital: 500,000 ATS
4 Mar 1994
Reg­is­tra­tion: 04/03/1994 · ppa (3) · MD (1) · SH: Boehringer Ingelheim International GmbH, Genentech Inc., San Franciso, USA · Address · Deadline for annual balance: 31.12. · Capital: 500,000 ATS
There are no publications matching your search.

Mentions

1 Sept 2025 in Ler
Direct parent: C.H. Boehringer Sohn AG & Co. KG
1 Sept 2025 in Ler
Ultimate parent: C.H. Boehringer Sohn AG & Co. KG
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "Forschungsinstitut für molekulare Pathologie GmbH, Vienna, Austria" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.